US Bancorp DE reduced its stake in shares of Biogen Inc. (NASDAQ:BIIB – Free Report) by 15.7% in the third quarter, according ...

Biogen (BIIB) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates ...

Market watchers, throughout the week, observed several Wall Street executives stepping up for new roles as part of leadership reshuffling. Meanwhile, some companies such as Biogen, U.S. Bancorp and ...

Fintel reports that on October 31, 2024, Morgan Stanley downgraded their outlook for Biogen (NasdaqGS:BIIB) from Overweight ...

Biogen's Q3 earnings report shows flat growth but highlights its value for risk-tolerant investors in CNS disease treatment.

Jefferies analyst Michael Yee maintained a Buy rating on Biogen (BIIB – Research Report) today and set a price target of $250.00. The ...

Biogen Inc BIIB reported upbeat earnings for the third quarter on Wednesday. The company pisted third-quarter adjusted EPS of ...

Biogen (NASDAQ:BIIB) shares slid around 3% Thursday after Morgan Stanley analysts downgraded the stock from Overweight to Equal Weight and slashed the price target from $285 to $204.

In a report released today, Mohit Bansal from Wells Fargo maintained a Hold rating on Biogen (BIIB – Research Report), with a price ...

At this time, I would like to welcome everyone to the Biogen third quarter 2024 earnings call and business update. [Operator ...

Biogen raised its full-year guidance and now expects adjusted EPS to range from $16.10 to $16.60, up from prior guidance of $15.75 to $16.25. It still expects revenue to fall by a low-single-digit ...

Biogen raised its annual profit forecast on Wednesday, as new treatments and cost-cutting measures offset declining sales of its multiple sclerosis drugs.